1,25-dihydroxy-16-ene-23-yne-vitamin d3 and prostate cancer cell proliferation in vivo

Gary Schwartz, Christopher C. Hill, Theresa A. Oeler, Michael J. Becich, Robert R. Bahnson

Research output: Contribution to journalArticle

119 Citations (Scopus)

Abstract

1,25-Dihydroxyvitamin D can inhibit the proliferation of prostate cancer cells, but its clinical use is limited by hypercalcemia. We examined the effects of a “noncalcemic” vitamin D analogue, 1,25-Dihydroxy-16-ene-23-yne-cholecalciferol (16-23-D3), on the proliferation of human prostate cancer cells in a mouse model. Twenty-four athymic nude mice were inoculated with human prostate carcinoma cells from the PC-3 cell line. Twelve mice (experimental group) received injections of 1.6 μg of 16-23-D3 on alternate days over a 22-day period. Twelve mice (control group) received sham injections. Tumor volumes, pathologic findings, and terminal serum calcium levels were compared between groups. The relative increase in tumor volume was significantly lower in the experimental than in the control group in the first interval following treatment (P < 0.01). Mean tumor volumes in the experimental group were approximately 15% smaller than in the control group. Serum calcium levels did not differ between groups. 16-23-D3 showed modest antiproliferative effects on prostate cancer cells in this model without evidence of drug-induced hypercalcemia. These findings support the concept that vitamin D analogues can inhibit the proliferation of human prostate cancer cells in vivo.

Original languageEnglish (US)
Pages (from-to)365-369
Number of pages5
JournalUrology
Volume46
Issue number3
DOIs
StatePublished - Jan 1 1995

Fingerprint

Prostatic Neoplasms
Cell Proliferation
Tumor Burden
Hypercalcemia
Nude Mice
Vitamin D
Control Groups
Calcium
Injections
Cholecalciferol
Serum
Prostate
Ro 23-7553
Carcinoma
Cell Line
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Urology

Cite this

1,25-dihydroxy-16-ene-23-yne-vitamin d3 and prostate cancer cell proliferation in vivo. / Schwartz, Gary; Hill, Christopher C.; Oeler, Theresa A.; Becich, Michael J.; Bahnson, Robert R.

In: Urology, Vol. 46, No. 3, 01.01.1995, p. 365-369.

Research output: Contribution to journalArticle

Schwartz, Gary ; Hill, Christopher C. ; Oeler, Theresa A. ; Becich, Michael J. ; Bahnson, Robert R. / 1,25-dihydroxy-16-ene-23-yne-vitamin d3 and prostate cancer cell proliferation in vivo. In: Urology. 1995 ; Vol. 46, No. 3. pp. 365-369.
@article{38378ff9aec54c9983d1e9eb9ac78880,
title = "1,25-dihydroxy-16-ene-23-yne-vitamin d3 and prostate cancer cell proliferation in vivo",
abstract = "1,25-Dihydroxyvitamin D can inhibit the proliferation of prostate cancer cells, but its clinical use is limited by hypercalcemia. We examined the effects of a “noncalcemic” vitamin D analogue, 1,25-Dihydroxy-16-ene-23-yne-cholecalciferol (16-23-D3), on the proliferation of human prostate cancer cells in a mouse model. Twenty-four athymic nude mice were inoculated with human prostate carcinoma cells from the PC-3 cell line. Twelve mice (experimental group) received injections of 1.6 μg of 16-23-D3 on alternate days over a 22-day period. Twelve mice (control group) received sham injections. Tumor volumes, pathologic findings, and terminal serum calcium levels were compared between groups. The relative increase in tumor volume was significantly lower in the experimental than in the control group in the first interval following treatment (P < 0.01). Mean tumor volumes in the experimental group were approximately 15{\%} smaller than in the control group. Serum calcium levels did not differ between groups. 16-23-D3 showed modest antiproliferative effects on prostate cancer cells in this model without evidence of drug-induced hypercalcemia. These findings support the concept that vitamin D analogues can inhibit the proliferation of human prostate cancer cells in vivo.",
author = "Gary Schwartz and Hill, {Christopher C.} and Oeler, {Theresa A.} and Becich, {Michael J.} and Bahnson, {Robert R.}",
year = "1995",
month = "1",
day = "1",
doi = "10.1016/S0090-4295(99)80221-0",
language = "English (US)",
volume = "46",
pages = "365--369",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - 1,25-dihydroxy-16-ene-23-yne-vitamin d3 and prostate cancer cell proliferation in vivo

AU - Schwartz, Gary

AU - Hill, Christopher C.

AU - Oeler, Theresa A.

AU - Becich, Michael J.

AU - Bahnson, Robert R.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - 1,25-Dihydroxyvitamin D can inhibit the proliferation of prostate cancer cells, but its clinical use is limited by hypercalcemia. We examined the effects of a “noncalcemic” vitamin D analogue, 1,25-Dihydroxy-16-ene-23-yne-cholecalciferol (16-23-D3), on the proliferation of human prostate cancer cells in a mouse model. Twenty-four athymic nude mice were inoculated with human prostate carcinoma cells from the PC-3 cell line. Twelve mice (experimental group) received injections of 1.6 μg of 16-23-D3 on alternate days over a 22-day period. Twelve mice (control group) received sham injections. Tumor volumes, pathologic findings, and terminal serum calcium levels were compared between groups. The relative increase in tumor volume was significantly lower in the experimental than in the control group in the first interval following treatment (P < 0.01). Mean tumor volumes in the experimental group were approximately 15% smaller than in the control group. Serum calcium levels did not differ between groups. 16-23-D3 showed modest antiproliferative effects on prostate cancer cells in this model without evidence of drug-induced hypercalcemia. These findings support the concept that vitamin D analogues can inhibit the proliferation of human prostate cancer cells in vivo.

AB - 1,25-Dihydroxyvitamin D can inhibit the proliferation of prostate cancer cells, but its clinical use is limited by hypercalcemia. We examined the effects of a “noncalcemic” vitamin D analogue, 1,25-Dihydroxy-16-ene-23-yne-cholecalciferol (16-23-D3), on the proliferation of human prostate cancer cells in a mouse model. Twenty-four athymic nude mice were inoculated with human prostate carcinoma cells from the PC-3 cell line. Twelve mice (experimental group) received injections of 1.6 μg of 16-23-D3 on alternate days over a 22-day period. Twelve mice (control group) received sham injections. Tumor volumes, pathologic findings, and terminal serum calcium levels were compared between groups. The relative increase in tumor volume was significantly lower in the experimental than in the control group in the first interval following treatment (P < 0.01). Mean tumor volumes in the experimental group were approximately 15% smaller than in the control group. Serum calcium levels did not differ between groups. 16-23-D3 showed modest antiproliferative effects on prostate cancer cells in this model without evidence of drug-induced hypercalcemia. These findings support the concept that vitamin D analogues can inhibit the proliferation of human prostate cancer cells in vivo.

UR - http://www.scopus.com/inward/record.url?scp=0028971107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028971107&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(99)80221-0

DO - 10.1016/S0090-4295(99)80221-0

M3 - Article

VL - 46

SP - 365

EP - 369

JO - Urology

JF - Urology

SN - 0090-4295

IS - 3

ER -